Adynxx, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADYX research report →
Price Chart
About the company
Adynxx, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating and commercializing novel transcription factor decoy technologies to combat pain and inflammatory conditions. Central to its efforts is the AYX platform of transcription factor decoys, which includes brivoligide, currently progressing through Phase II clinical development for reducing post-surgical discomfort.
- CEO
- Richard Orr
- IPO
- 1998
- Employees
- 6
- HQ
- San Francisco, CA, US
Get TickerSpark's AI analysis on ADYX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $581
- P/E
- -0.00
- Fwd P/E
- 0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 2.60
- Div Yield
- 0.00%
- Gross Margin
- 22.38%
- Op Margin
- -238.99%
- Net Margin
- -379.83%
- ROE
- -70.38%
- ROIC
- -63.78%
Latest fiscal year · YoY change
- Revenue
- $2.22M+9.8%
- Gross Profit
- $496.00K+178.7%
- Op Income
- $-5,296,000
- Net Income
- $-8,417,000+67.3%
- EPS
- $-10.26+71.5%
- OCF Growth
- +9.0%
- FCF Growth
- +10.5%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -8.54
- RSI (14)
- 52
- Avg Volume
- 5
No earnings-call transcripts are available for ADYX yet.
- Free Float
- 36.9%
- Shares Outstanding
- 5.81M
- Float Shares
- 2.14M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 22, 19 | FLESHER GREGORY J. | other | 0 |
| Jun 21, 19 | Adynxx, Inc. | other | 0 |
| May 29, 19 | GONZALEZ DINA | other | 26,358 |
| May 29, 19 | GONZALEZ DINA | other | 1,577 |
| May 29, 19 | GONZALEZ DINA | other | 1,577 |
| May 3, 19 | TPG Group Holdings (SBS) Advisors, Inc. | other | 0 |
| May 3, 19 | DP VIII Associates, L.P. | other | 0 |
| May 3, 19 | Domain Partners VIII, L.P. | other | 0 |
| May 3, 19 | ABEL STAN E | other | 54,117 |
| May 3, 19 | ABEL STAN E | other | 27,940 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ADYX coverage
Recent articles, reports, and earnings notes.
No research on ADYX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ADYX report →